(EOLS) Evolus - Overview

Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NASDAQ (USA) | Market Cap: 401m USD | Total Return: -29.8% in 12m

Botulinum Toxin, Dermal Fillers, Hyaluronic Acid
Total Rating 27
Safety 35
Buy Signal -0.51
Drug Manufacturers - Specialty & Generic
Industry Rotation: -4.2
Market Cap: 401M
Avg Turnover: 5.06M
Risk 3d forecast
Volatility56.1%
VaR 5th Pctl8.59%
VaR vs Median-8.65%
Reward TTM
Sharpe Ratio-0.23
Rel. Str. IBD53.4
Rel. Str. Peer Group53.9
Character TTM
Beta0.922
Beta Downside0.747
Hurst Exponent0.533
Drawdowns 3y
Max DD77.47%
CAGR/Max DD-0.12
CAGR/Mean DD-0.31
EPS (Earnings per Share) EPS (Earnings per Share) of EOLS over the last years for every Quarter: "2021-03": -0.2, "2021-06": -0.19, "2021-09": -0.27, "2021-12": -0.22, "2022-03": -0.22, "2022-06": -0.28, "2022-09": -0.28, "2022-12": -0.14, "2023-03": -0.15, "2023-06": -0.19, "2023-09": -0.16, "2023-12": -0.12, "2024-03": -0.09, "2024-06": -0.04, "2024-09": -0.16, "2024-12": 0.0139, "2025-03": -0.17, "2025-06": -0.27, "2025-09": -0.24, "2025-12": 0.0132, "2026-03": -0.0495,
Last SUE: 1.16
Qual. Beats: 1
Revenue Revenue of EOLS over the last years for every Quarter: 2021-03: 12.241, 2021-06: 26.098, 2021-09: 26.677, 2021-12: 34.657, 2022-03: 33.908, 2022-06: 37.163, 2022-09: 33.899, 2022-12: 43.646, 2023-03: 41.721, 2023-06: 49.346, 2023-09: 50.019, 2023-12: 60.999, 2024-03: 59.333, 2024-06: 66.909, 2024-09: 61.085, 2024-12: 78.947, 2025-03: 68.522, 2025-06: 69.387, 2025-09: 68.967, 2025-12: 90.3, 2026-03: 73.137,
Rev. CAGR: 23.00%
Rev. Trend: 96.7%
Last SUE: 0.21
Qual. Beats: 0

Warnings

Negative Equity with losses - insolvent profile

Interest Coverage Ratio -1.2 is critical

Altman Z'' -11.37 < 1.0 - financial distress zone

Choppy

Tailwinds

No distinct edge detected

Description: EOLS Evolus

Evolus, Inc. (EOLS) is a performance beauty company specializing in the self-pay aesthetic market. Its primary product, Jeuveau, is a 900 kDa purified botulinum toxin type A designed to treat moderate to severe glabellar lines. The company also maintains a portfolio of hyaluronic acid dermal fillers under the Evolysse brand, targeting facial areas such as the lips, eyes, and nasolabial folds.

Operating within the aesthetics sector, Evolus focuses on a cash-pay business model, which eliminates the complexities of third-party insurance reimbursement and focuses directly on consumer discretionary spending. The global medical aesthetics market is characterized by high patient loyalty and recurring revenue cycles due to the temporary nature of injectable treatments. Further examination of these market dynamics on ValueRay can help clarify the companys long-term positioning.

Headquartered in Newport Beach, California, Evolus distributes its products across the United States, Canada, Europe, and Australia. The company competes directly with established pharmaceutical firms by focusing exclusively on aesthetic indications rather than therapeutic applications.

Headlines to Watch Out For
  • Jeuveau market share gains against incumbents drive core aesthetic neurotoxin revenue growth
  • Commercial launch of Evolysse dermal filler line expands total addressable market potential
  • High exposure to discretionary consumer spending impacts cash-pay aesthetic procedure volume
  • Sales force expansion costs and marketing investments influence near-term operating margins
  • Legal and regulatory developments surrounding botulinum toxin manufacturing impact long-term supply stability
Piotroski VR-10 (Strict) 3.0
Net Income: -43.4m TTM > 0 and > 6% of Revenue
FCF/TA: -0.19 > 0.02 and ΔFCF/TA -5.18 > 1.0
NWC/Revenue: 23.49% < 20% (prev 27.40%; Δ -3.91% < -1%)
CFO/TA -0.17 > 3% & CFO -36.6m > Net Income -43.4m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 2.04 > 1.5 & < 3
Outstanding Shares: last quarter (65.2m) vs 12m ago 2.34% < -2%
Gross Margin: 65.55% > 18% (prev 0.68%; Δ 6.49k% > 0.5%)
Asset Turnover: 139.1% > 50% (prev 129.1%; Δ 9.97% > 0%)
Interest Coverage Ratio: -1.21 > 6 (EBITDA TTM -14.0m / Interest Expense TTM 19.3m)
Altman Z'' -11.37
A: 0.32 (Total Current Assets 138.9m - Total Current Liabilities 68.0m) / Total Assets 220.6m
B: -3.04 (Retained Earnings -671.7m / Total Assets 220.6m)
C: -0.11 (EBIT TTM -23.3m / Avg Total Assets 217.0m)
D: -2.69 (Book Value of Equity -672.0m / Total Liabilities 249.4m)
Altman-Z'' = -11.37 = D
Beneish M -2.99
DSRI: 1.00 (Receivables 52.2m/47.5m, Revenue 301.8m/275.5m)
GMI: 1.04 (GM 65.55% / 67.86%)
AQI: 0.94 (AQ_t 0.32 / AQ_t-1 0.33)
SGI: 1.10 (Revenue 301.8m / 275.5m)
TATA: -0.03 (NI -43.4m - CFO -36.6m) / TA 220.6m)
Beneish M = -2.99 (Cap -4..+1) = A
What is the price of EOLS shares?

As of May 30, 2026, the stock is trading at USD 6.56 with a total of 799,081 shares traded.
Over the past week, the price has changed by +1.71%, over one month by +26.64%, over three months by +52.56% and over the past year by -29.76%.

Is EOLS a buy, sell or hold?

Evolus has received a consensus analysts rating of 4.57. Therefore, it is recommended to buy EOLS.

  • StrongBuy: 4
  • Buy: 3
  • Hold: 0
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the EOLS price?
Analysts Target Price 14.7 123.6%
Evolus (EOLS) - Fundamental Data Overview as of 24 May 2026
Market Cap USD = 401.1m (401.1m USD * 1.0 USD.USD)
P/E Forward = 55.2486
P/S = 1.3289
P/B = 53.7058
Revenue TTM = 301.8m USD
EBIT TTM = -23.3m USD
EBITDA TTM = -14.0m USD
Long Term Debt = 156.4m USD (from longTermDebt, last quarter)
Short Term Debt = 2.55m USD (from shortTermDebt, last quarter)
Debt = 173.4m USD (from shortLongTermDebtTotal, last quarter) + Leases 8.49m
Net Debt = 123.6m USD (calculated: Debt 173.4m - CCE 49.8m)
Enterprise Value = 524.7m USD (401.1m + Debt 173.4m - CCE 49.8m)
Interest Coverage Ratio = -1.21 (Ebit TTM -23.3m / Interest Expense TTM 19.3m)
EV/FCF = -12.70x (Enterprise Value 524.7m / FCF TTM -41.3m)
FCF Yield = -7.88% (FCF TTM -41.3m / Enterprise Value 524.7m)
FCF Margin = -13.69% (FCF TTM -41.3m / Revenue TTM 301.8m)
Net Margin = -14.39% (Net Income TTM -43.4m / Revenue TTM 301.8m)
Gross Margin = 65.55% ((Revenue TTM 301.8m - Cost of Revenue TTM 104.0m) / Revenue TTM)
Gross Margin QoQ = 64.75% (prev 65.66%)
Tobins Q-Ratio = 2.38 (Enterprise Value 524.7m / Total Assets 220.6m)
Interest Expense / Debt = 11.10% (Interest Expense 19.3m / Debt 173.4m)
Taxrate = 21.0% (US default 21%)
NOPAT = -18.4m (EBIT -23.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.04 (Total Current Assets 138.9m / Total Current Liabilities 68.0m)
 Debt / Equity = -6.02 (negative equity) (Debt 173.4m / totalStockholderEquity, last quarter -28.8m)
 Debt / EBITDA = -8.81 (negative EBITDA) (Net Debt 123.6m / EBITDA -14.0m)
 Debt / FCF = -2.99 (negative FCF - burning cash) (Net Debt 123.6m / FCF TTM -41.3m)
 Total Stockholder Equity = -24.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -20.01% (Net Income -43.4m / Total Assets 220.6m)
RoE = -6.71% (Net Income TTM -43.4m / Total Stockholder Equity 646.9m)
RoCE = -2.90% (EBIT -23.3m / Capital Employed (Equity 646.9m + L.T.Debt 156.4m))
 RoIC = -17.47% (negative operating profit) (NOPAT -18.4m / Invested Capital 105.4m)
 WACC = 9.08% (E(401.1m)/V(574.4m) * Re(9.22%) + D(173.4m)/V(574.4m) * Rd(11.10%) * (1-Tc(0.21)))
Discount Rate = 9.22% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 91.11 | Cagr: 5.94%
 [DCF] Fair Price = unknown (Cash Flow -41.3m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.16 | # QB: 1
Revenue Correlation: 96.68 | Revenue CAGR: 23.00% | SUE: 0.21 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.04 | Chg30d=+8.99% | Revisions=-20% | Analysts=4
EPS next Quarter (2026-09-30): EPS=-0.07 | Chg30d=-23.46% | Revisions=+0% | Analysts=3
EPS current Year (2026-12-31): EPS=-0.09 | Chg30d=+22.95% | Revisions=+33% | GrowthEPS=+78.6% | GrowthRev=+11.2%
EPS next Year (2027-12-31): EPS=0.27 | Chg30d=+11.13% | Revisions=+14% | GrowthEPS=+383.7% | GrowthRev=+17.3%
[Analyst] Revisions Ratio: +33%